Candel Therapeutics, Inc. (CADL) - Uzoq muddatli qarzning kapitalga nisbati
GURU.Markets platformasida quyida tasvirlangan Candel Therapeutics (CADL) aksiyalarining joriy kotirovkalari virusli o'smalarga qarshi kurashish usullarini ishlab chiqishga asoslangan bo'lib, markazlarda uzoq muddatli qolish barqaror daromadni kafolatlaydi. Xodimlar barqarorligi opsionlar va top-menejerlarni ishga olish orqali ta'minlanadi, bunda ko'rsatkich 0.41 darajasida turibdi. Yakuniy natija testlardagi omon qolish darajasi, investitsiyalar mavjudligi va yangi agentlarning klassik terapiya bilan mos kelishiga bog'liq.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_CADL_-_Candel-Therapeutics_-_Long-Term-Debt-to-Equity "Candel Therapeutics Inc. (CADL): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 04.07.2022dan 30.10.2026gacha | 👁️GURU.Markets👁️")
Candel Therapeutics kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Candel Therapeutics|CADL - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Candel|CADL - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Candel Therapeutics, Inc.|CADL - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Candel Therapeutics|Tezkor likvidlik koeffitsiyenti candeltx.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning umumiy tahlili:candeltx.com - CADL
Professional kapital bankrotlik xavflarini bartaraf etish uchun qarz va kapital muvozanati orqali emitentning moliyaviy barqarorligini baholaydi. Uzoq muddatli qarzning kapitalga nisbati tarixini tahlil qilish orqali investor muddati bir yildan oshadigan kreditlar ulushini aniqlaydi, bu esa Candel Therapeutics (CADL) rahbariyatining yuqori ilmiy ekspertizasi bilan birgalikda boshqaruv shaffofligini va aktivning ishonchliligini tasdiqlaydi.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati AURA (Aura Biosciences)|ARAY (Accuray Inc) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati SLS (SELLAS Life Sciences Group)|ACTU - Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR: Uzoq muddatli qarzning o'z kapitaliga nisbati|HURA - Uzoq muddatli qarzning kapitalga nisbati|Protara Therapeutics, Inc. (TARA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Fate Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati TScan TCRX|Uzoq muddatli qarzning kapitalga nisbati CSBR|Uzoq muddatli qarzning o'z kapitaliga nisbati xbiotech.com XBIT|Uzoq muddatli qarzning kapitalga nisbati CVM (CEL-SCI)|Uzoq muddatli qarzning kapitalga nisbati OS Therapies Inc. OSTX|RADX - Uzoq muddatli qarzning o'z kapitaliga nisbati|ARTV (Artiva Biotherapeutics, Inc.) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|ANL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi VERU|TPST (Tempest Therapeutics, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Xilio XLO|Uzoq muddatli qarzning o'z kapitaliga nisbati Renovaro Inc. (RENB)|Uzoq muddatli qarzning o'z kapitaliga nisbati MURA (muraloncology.com)|Kairos Pharma - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti OKUR|GDTC: Uzoq muddatli qarzning o'z kapitaliga nisbati|Curis, Inc. - Uzoq muddatli kreditlarning kapitalga nisbati|APLM: Uzoq muddatli qarzning kapitalga nisbati|Tharimmune Corporation - Uzoq muddatli qarzning kapitalga koeffitsiyenti|ADVB (Advanced Biomed Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati genprex.com GNPX|Uzoq muddatli qarzning o'z kapitaliga nisbati Calidi Biotherapeutics (CLDI)|SBFM (Sunshine Biopharma Inc.) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati XBIO (Xenetic Biosciences, Inc.)|Uzoq muddatli qarzning kapitalga nisbati Salarius Pharma SLRX|PPBT - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati AONC|BGNE: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Checkpoint Therapeutics Inc. (CKPT)|Uzoq muddatli qarzning o'z kapitaliga nisbati ELEV|Uzoq muddatli qarzning kapitalga nisbati iCAD Corp|Uzoq muddatli qarzning o'z kapitaliga nisbati IKNA (Ikena Oncology, Inc.)|Uzoq muddatli kreditlarning kapitalga nisbati NTBL|Uzoq muddatli qarzning kapitalga nisbati VIRX (Viracta Therapeutics, Inc.)|Uzoq muddatli qarzdorlikning kapitalga nisbati MorphoSys Inc (MOR)|NAYA Bio - Uzoq muddatli qarzning kapitalga nisbati|Ascentage (AAPGV) - Uzoq muddatli qarzning o'z kapitaliga nisbati